Molecular basis of the Dark Agouti rat drug oxidation polymorphism: Importance of CYP2D1 and CYP2D2

Pharmacogenetics

Volumn 8, Issue 1, 1998, Pages 73-82

  Yamamoto, Yukio ^a   Tasaki, Takafumi ^a   Nakamura, Akio ^a,c   Iwata, Hisato ^a   Kazusaka, Akio ^a   Gonzalez, Frank J ^b   Fujita, Shoichi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NIPPON SHINYAKU CO LTD   (Japan)

Author keywords

Bunitrolol; CYP2D; Cytochrome P450; Polymorphism; Poor metabolizer

Indexed keywords

BUNITROLOL; CYTOCHROME P450;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG METABOLISM; DRUG OXIDATION; GENE EXPRESSION REGULATION; GENE EXPRESSION SYSTEM; LEPIDOPTERA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RAT;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BACULOVIRIDAE; CELL LINE; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENE EXPRESSION; HUMANS; MALE; PHENOTYPE; POLYMORPHISM, GENETIC; PROPANOLAMINES; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; RNA, MESSENGER; SPODOPTERA;

AGOUTI; ANIMALIA; INSECTA; LEPIDOPTERA; RODENTIA; SPODOPTERA FRUGIPERDA; UNIDENTIFIED BACULOVIRUS;

EID: 0031882863     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199802000-00010     Document Type: Article

References (37)

1. Al-Dabbagh SG, Idle JR, Smith RL. Animal modelling of human polymorphic drug oxidation: the metabolism of debrisoquine and phenacetin in rat inbred strains. J Pharm Pharmacol 1981; 33, 161-164.
2. Ardies CM, Lasker JM, Bloswick BP, Lieber CS. Purification of NADPH: cytochrome c (cytochrome P-450) reductase from hamster liver microsomes by detergent extraction and affinity chromatography. AnalBiochem 1987; 162, 39-46.
3. Brosen K. Recent developments in hepatic drug oxidation: implications for clinical pharmacokinetics. Clin Pharmacokinet 1990; 18, 220-239.
4. Brosen K, Klysner R, Gram LF, Otton SV, Bech P, Bertilsson L. Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism. Bur J Clin Pharmacol 1986; 30, 679-684.
5. Buters JT, Shou M, Hardwick JP, Korzekwa KR, Gonzalez FJ. cDNA-directed expression of human cytochrome P450 CYP1A1 using baculovirus: purification, dependency on NADPH-P450 oxidoreductase, and reconstitution of catalytic properties without purification. Drug Metab Dispos 1995; 23, 696-701.
6. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162, 156-159.
7. Daly AK, Brockmoller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, Huang JD, Idle JR, Ingelman-Sundberg M, Ishizaki T, et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996; 6, 193-201.
8. Distlerath LM, Reilly PE, Martin MV, Davis GG, Wilkinson GR, Guengerich FP. Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation: two prototypes for genetic polymorphism in oxidative drug metabolism. J. Biol Chem 1985; 260, 9057-9067.
9. Eichelbaum M, Gross AS. The genetic polymorphism of debrisoquine/sparteine metabolism: clinical aspects. Pharmacol Therapeut 1990; 46, 377-394.
10. Fujita S, Umeda S, Funae Y, Imaoka S, Abe H, Ishida R, Adachi T, Masuda M, Kazusaka A, Suzuki T. Regio- and stereoselective propranolol metabolism by 15 forms of purified cytochromes P-450 from rat liver. J Pharmacol Exp Ther 1993; 264, 226-233.
11. Gonzalez FJ. The CYP2D subfamily. In: Ioannides C, ed. Cytochromes P450: metabolic and toxicological aspects. Boca Raton: CRC Press, 1996; 183-210.
12. Gonzalez FJ, Matsunaga T, Nagata K, Meyer UA, Nebert DW, Pastewka J, Kozak CA, Gillette J, Gelboin HV, Hardwick JP. Debrisoquine 4-hydroxylase: characterization of a new P450 gene subfamily, regulation, chromosomal mapping, and molecular analysis of the DA rat polymorphism. DNA 1987; 6, 149-161.
13. Gonzalez FJ, Skoda RC, Kimura S, Umeno M, Zanger UM, Nebert DW, Gelboin HV, Hardwick JP, Meyer UA. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 1988; 331, 442-446.
14. Gough AC, Miles JS, Spurr NK, Moss JE, Gaedigk A, Eichelbaum M, Wolf CR. Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature 1990; 347, 773-776.
15. Grogan J, Shou M, Andrusiak EA, Tamura S, Buters JT, Gonzalez FJ, Korzekwa KR. Cytochrome P450 2A1, 2E1, and 2C9 cDNA-expression by insect cells and partial purification using hydrophobic chromatography. Biochem Pharmacol 1995; 50, 1509-1515.
16. Gut J, Catin T, Dayer P, Kronbach T, Zanger U, Meyer UA. Debrisoquine/sparteine-type polymorphism of drug oxidation: purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol. J Biol Chem 1986; 261, 11734-11743.
17. Harada N. Novel properties of human placental aromatase as cytochrome P-450: purification and characterization of a unique form of aromatase. J Biochem 1988; 103, 106-113.
18. Itoh S, Satoh M, Abe Y, Hashimoto H, Yanagimoto T, Kamataki T. A novel form of mouse cytochrome P450 3A (Cyp3a-16): its cDNA cloning and expression in fetal liver. Eur J Biochem 1994; 226, 877-882.
19. Kahn GC, Rubenfield M, Davies DS, Murray S, Boobis AR. Sex and strain differences in hepatic debrisoquine 4-hydroxylase activity of the rat. Drug Metab Dispos 1985; 13, 510-516.
20. Kobayashi S, Murray S, Watson D, Sesardic D, Davies DS, Boobis AR. The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rat is the inverse of that in man. Biochem Pharmacol 1989; 38, 2795-2799.
21. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227, 680-685.
22. Larrey D, Distlerath LM, Dannan GA, Wilkinson GR, Guengerich FP. Purification and characterization of the rat liver microsomal cytochrome P-450 involved in the 4-hydroxylation of debrisoquine: a prototype for genetic variation in oxidative drug metabolism. Biochemistry 1984; 23, 2787-2795.
23. Lennard PR. Image analysis for all. Nature 1990; 347, 103-104.
24. Lowry OH, Rosebrough NJ, Farr AL. Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193, 265-275.
25. Matsunaga E, Zanger UM, Hardwick JP, Gelboin HV, Meyer UA, Gonzalez FJ. The CYP2D gene subfamily: analysis of the molecular basis of the debrisoquine 4-hydroxylase deficiency in DA rats. Biochemistry 1989; 28, 7349-7355.
26. Matsunaga E, Umeno M, Gonzalez FJ. The rat P450 IID subfamily: complete sequences of four closely linked genes and evidence that gene conversions maintained sequence homogeneity at the heme-binding region of the cytochrome P450 active site. J Mol Evol 1990; 30, 155-169.
27. Nakamura A, Yamamoto Y, Tasaki T, Sugimoto C, Masuda M, Kazusaka A, Fujita S. Anti-peptide antibodies to the P4502D subfamily in rat, dog and man. Xenobiotica 1995; 25, 1103-1109.
28. Narimatsu S, Masubuchi Y, Hosokawa S, Ohmori S, Kitada M, Suzuki T. Involvement of a cytochrome P4502D subfamily in human liver microsomal bunitrolol 4-hydroxylation. Biol Pharm Bull 1994; 17, 803-807.
29. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996; 6, 1-12.
30. Ohishi N, Imaoka S, Suzuki T, Funae Y. Characterization of two P-450 isozymes placed in the rat CYP2D subfamily. Biochim Biophys Acta 1993; 1158, 227-236.
31. Omura T, Sato R. The carbon monoxide-binding pigment of liver microsomes: II. solubilization, purification, and properties. J Biol Chem 1964; 239, 2379-2385.
32. Osikowska-Evers B, Dayer P, Meyer UA, Robertz GM, Eichelbaum M. Evidence for altered catalytic properties of the cytochrome P-450 involved in sparteine oxidation in poor metabolizers. Clin Pharmacol Ther 1987; 41, 320-325.
33. Otton SV, Tyndale RF, Wu D, Inaba T, Kalow W, Sellers EM. Catalytic and immunologie similarities between monkey and human liver cytochrome P-450db1 (human cytochrome P-450 2D6). Drug Metab Dispos 1992; 20, 1-5.
34. Raghuram TC, Koshakji RP, Wilkinson GR, Wood AJ. Polymorphic ability to metabolize propranolol alters 4-hydroxypropranolol levels but not beta blockade. Clin Pharmacol Ther 1984; 36, 51-56.
35. Suzuki T, Narimatsu S, Fujita S, Masubuchi Y, Umeda S. Impairment of bunitrolol 4-hydroxylase activity in liver microsomes of dark agouti rats. Biochem Pharmacol 1991; 42, 2241-2244.
36. Suzuki T, Narimatsu S, Fujita S, Masubuchi Y, Umeda S, Imaoka S, Funae Y. Purification and characterization of a cytochrome P-450 isozyme catalyzing bunitrolol 4-hydroxylation in liver microsomes of male rats. Drug Metab Dispos 1992; 20, 367-373.
37. Yamamoto Y, Nakamura A, Tasaki T, Umeda S, Sugimoto C, Imaoka S, Funae Y, Masuda M, Kazusaka A, Fujita S. Impaired expression in DA rats of catalytically active P450BTL, immunochemically distinguishable from P4502D1: immunological evidence with specific anti-peptide antibodies. Biomed Res 1996; 17, 331-337.